ClinicalTrials.gg
CompletedNCT02099461Updated Sep 24, 2015Results posted

Effect of Denosumab on Cellular Biomarkers in the Human Breast

A Phase 1 interventional study of Denosumab and Percutaneous core needle breast biopsy in Healthy Volunteer, Female, Breast, sponsored by Amgen. Completed at 3 sites in United States. Open to female participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-09-24.

Sponsored by Amgen · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
82
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Female
01

Study summary

To evaluate whether administration of denosumab results in a decrease compared to the control group in proliferation of mammary epithelial cells as measured by the Ki-67 proliferation index.

02

Conditions studied

  • Healthy Volunteer, Female, Breast
03

In context

Lead sponsor

Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.

Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Willing to use, in combination with her partner, 2 non-hormonal methods of effective or practice sexual abstinence. Subjects who are surgically sterile (eg, history of hysterectomy) or whose sexual partner is sterile (eg, history of vasectomy) are not required to use contraceptive measures
  • Laboratory tests are within clinically acceptable range
  • Clinically acceptable physical exam and no history or evidence of any medical disorder that would pose a risk to subject safety or interfere with study evaluations or procedures.

Exclusion criteria

EXCLUSION CRITERIA:

  • Female subject with a prior history of breast cancer; breast implant in the breast to be biopsied; Known history of fibrocystic breast disease
  • Subject is unable or unwilling to provide breast tissue from the upper outer quadrant of her breast
  • Pregnant or plans to become pregnant while exposed to product
  • Lactating/breastfeeding or plans to breastfeed while exposed to investigational product
  • Recent use of any non-approved medications or devices
  • Uncontrolled thyroid disorder
  • Significant dental/oral disease
  • Planned invasive dental procedures
  • Positive urine screen for alcohol and/or drugs
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
82 participants (actual)

Study arms

  • Other
    No treatment

    Participants received no treatment and underwent percutaneous core needle breast biopsies on Day 1 and Day 28.

    Procedure: Percutaneous core needle breast biopsy

  • Experimental
    Denosumab 60 mg

    Participants received 60 mg denosumab by subcutaneous injection on Day 1 and underwent percutaneous core needle breast biopsies on Day 1 (prior to study treatment) and Day 28.

    Drug: Denosumab · Procedure: Percutaneous core needle breast biopsy

  • Experimental
    Denosumab 120 mg

    Participants received 120 mg denosumab by subcutaneous injection on Day 1 and underwent percutaneous core needle breast biopsies on Day 1 (prior to study treatment) and Day 28.

    Drug: Denosumab · Procedure: Percutaneous core needle breast biopsy

Interventions

  • Single sucutaneous dose

  • ProcedurePercutaneous core needle breast biopsy
06

What researchers measure

Primary outcomes

  1. Log Ratio of Post-baseline to Baseline Ki-67 Index in Mammary Epithelial Cells

    Ki-67 is a marker for cell proliferation. Participants underwent percutaneous core needle breast biopsies on Day 1 (Baseline, prior to treatment) and Day 28. Levels of Ki67 were measured using immunohistochemical staining and digital imaging. The proliferation index was calculated as the percentage of Ki-67 positive terminal ductal lobular unit (TDLU) and duct epithelial cells. The higher the percentage, the higher the rate of epithelial cell proliferation.

    Time frame: Baseline and Day 28

07

Results

Posted Sep 24, 2015

Participant flow

Participant flow — Overall Study
MilestoneNo TreatmentDenosumab 60 mgDenosumab 120 mg
Started272728
Completed272728
Not completed000

Outcome measures

PrimaryLog Ratio of Post-baseline to Baseline Ki-67 Index in Mammary Epithelial Cells

Ki-67 is a marker for cell proliferation. Participants underwent percutaneous core needle breast biopsies on Day 1 (Baseline, prior to treatment) and Day 28. Levels of Ki67 were measured using immunohistochemical staining and digital imaging. The proliferation index was calculated as the percentage of Ki-67 positive terminal ductal lobular unit (TDLU) and duct epithelial cells. The higher the percentage, the higher the rate of epithelial cell proliferation.

Time frame:
Baseline and Day 28
Reported as:
Mean · log ratio
Log Ratio of Post-baseline to Baseline Ki-67 Index in Mammary Epithelial Cells
log ratioNo TreatmentDenosumab 60 mgDenosumab 120 mg
Log Ratio of Post-baseline to Baseline Ki-67 Index in Mammary Epithelial Cells0.084 ± 0.645-0.100 ± 1.048-0.081 ± 0.918
Statistical analysis
  • No Treatment · ANCOVA · p = 0.2966 · Ls mean: 0.15 · 95% CI -0.136 to 0.441
  • Denosumab 60 mg · ANCOVA · p = 0.2769 · Ls mean: -0.16 · 95% CI -0.447 to 0.130
  • Denosumab 120 mg · ANCOVA · p = 0.5238 · Ls mean: -0.09 · 95% CI -0.373 to 0.191
  • No Treatment vs Denosumab 60 mg · ANCOVA · p = 0.1343 · Ls mean difference: -0.31 · 95% CI -0.720 to 0.098Denosumab 60 mg - Placebo
  • No Treatment vs Denosumab 120 mg · ANCOVA · p = 0.2345 · Ls mean difference: -0.24 · 95% CI -0.646 to 0.161Denosumab 120 mg - Placebo

Adverse events

Collected over 28 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Treatment A No Treatment—0/27 (0%)4/27 (14.8%)
Treatment B 60 MG SC—0/27 (0%)6/27 (22.2%)
Treatment C 120 MG SC—0/28 (0%)11/28 (39.3%)
Most frequent other events
Most frequent other events
EventTreatment A No TreatmentTreatment B 60 MG SCTreatment C 120 MG SC
Injection site erythemaGeneral disorders0/271/2710/28
Procedural painInjury, poisoning and procedural complications4/274/272/28
Breast haematomaReproductive system and breast disorders0/272/270/28
HeadacheNervous system disorders0/270/272/28

Baseline characteristics

Age, Continuous
Age, Continuous(years)No TreatmentDenosumab 60 mgDenosumab 120 mgTotal
Mean29.9 ± 7.332.2 ± 7.632.8 ± 8.832.5 ± 8.2
Sex: Female, Male
Sex: Female, Male(Participants)No TreatmentDenosumab 60 mgDenosumab 120 mgTotal
Female27272882
Male0000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)No TreatmentDenosumab 60 mgDenosumab 120 mgTotal
Asian0011
Black (or African American)481022
Multiple1001
Native Hawaiian or Other Pacific Islander1012
Whte21191656
08

Study locations

3 sites
  • Research Site
    Cypress, California 90630, United States
  • Research Site
    Hollywood, Florida 33024, United States
  • Research Site
    Miami, Florida 33143, United States
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2014, a primary completion of Jul 2014 and a completion of Jul 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2015, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 25, 2014
First posted
Mar 31, 2014
Start
Apr 2014
Primary completionActual
Jul 2014
CompletionActual
Jul 2014
Results first posted
Sep 24, 2015
Last update
Sep 24, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 24, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02099461
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Mar 31, 2014
Start date
Apr 2014
Primary completion
Jul 2014
Completion
Jul 2014
Results posted
Sep 24, 2015
Last update
Sep 24, 2015

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Denosumab

Start the discussion